Similar articles

• Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.

  Gustavsson A, Van Der Putt R, Jönsson L, McShane R. Gustavsson A, et al. Int J Geriatr Psychiatry. 2009 Oct;24(10):1072-8. doi: 10.1002/gps.2223. Int J Geriatr Psychiatry. 2009. PMID: 19639600
• Health economics: basic principles and application in mental health.

  Suh GH. Suh GH. Int Psychogeriatr. 2007 Dec;19(6):993-1002. doi: 10.1017/s1041610206004558. Int Psychogeriatr. 2007. PMID: 18161066 No abstract available.
• Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.

  Behrens S, Rattinger GB, Schwartz S, Matyi J, Sanders C, DeBerard MS, Lyketsos CG, Tschanz JT. Behrens S, et al. Int Psychogeriatr. 2018 Oct;30(10):1499-1507. doi: 10.1017/S104161021800011X. Epub 2018 Mar 21. Int Psychogeriatr. 2018. PMID: 29559029 Free PMC article.
• Economics of dementia and pharmacoeconomics of dementia therapy.

  Fillit H, Hill J. Fillit H, et al. Am J Geriatr Pharmacother. 2005 Mar;3(1):39-49. doi: 10.1016/j.amjopharm.2005.03.005. Am J Geriatr Pharmacother. 2005. PMID: 16089246 Review.
• The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?

  Khang P, Weintraub N, Espinoza RT. Khang P, et al. J Am Med Dir Assoc. 2004 Jul-Aug;5(4):249-55. doi: 10.1097/01.JAM.0000131500.41375.1D. J Am Med Dir Assoc. 2004. PMID: 15228635 Review. No abstract available.